BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37722593)

  • 1. UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol.
    Rowen D; Mukuria C; Bray N; Carlton J; Cooper S; Longworth L; Meads D; O'Neill C; Yang Y
    Value Health; 2023 Nov; 26(11):1625-1635. PubMed ID: 37722593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
    Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
    Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
    Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing health-related quality of life: An EQ-5D-5L value set for England.
    Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. German Value Set for the EQ-5D-5L.
    Ludwig K; Graf von der Schulenburg JM; Greiner W
    Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
    Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
    Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
    Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
    Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study.
    Jyani G; Yang Z; Sharma A; Goyal A; Stolk E; Purba FD; Grover S; Kaur M; Prinja S
    Med Decis Making; 2023 Aug; 43(6):692-703. PubMed ID: 37480281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol.
    Yang F; Katumba KR; Roudijk B; Yang Z; Revill P; Griffin S; Ochanda PN; Lamorde M; Greco G; Seeley J; Sculpher M
    Pharmacoeconomics; 2022 Mar; 40(3):309-321. PubMed ID: 34841471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public versus patient health preferences: protocol for a study to elicit EQ-5D-5L health state valuations for patients who have survived a stay in intensive care.
    Halling CMB; Gudex C; Perner A; Jensen CE; Gyrd-Hansen D
    BMJ Open; 2022 May; 12(5):e058500. PubMed ID: 35613809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
    Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
    BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.